ST2 provides new insight on cardiovascular disease progression—relevant disease state information not reflected by other biomarkers and clinical observations.

Multiple published studies by leading investigators from around the world have demonstrated that ST2 is the most prognostic cardiac biomarker available, helping physicians make better treatment decisions than solely relying on clinical parameters and existing laboratory assays.

While BNP and NT-proBNP may help a physician diagnose heart failure in a symptomatic patient, ST2 is most useful in determining the patient's likely prognosis, regardless of their symptom status. Furthermore, ST2 enhances prognosis when used in conjunction with natriuretic peptide markers.

PLEASE CLICK HERE to access a list of peer-reviewed articles.